Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Sponsor: Prabesh Kanel • ClinicalTrials.gov ID: NCT07863180
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
Interventions
-
Tributyrin
(Drug)
Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.
-
Placebo
(Drug)
Participants will take 500mg TID placebo for 90 days +/- 7 days.
Eligibility criteria
Conditions
Locations
- Domino's Farms — Ann Arbor, Michigan, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record